Insiders · HRTX

HRTX insider transactions

Heron Therapeutics Inc. (HRTX) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for HRTX

• 31d
  Chief Operating Officer Hensley Mark Earl converted options into 125,000 shares, increasing direct ownership by 1,062% to 136,770 units (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 34d
  Chief Operating Officer Hensley Mark Earl converted options into 11,770 shares (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 34d
  EVP, Chief Development Officer Forbes William P converted options into 23,464 shares, increasing direct ownership by 13% to 209,111 units (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 34d
  EVP, Chief Financial Officer Duarte Ira converted options into 25,229 shares, increasing direct ownership by 17% to 252,128 units (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 34d
  Chief Executive Officer Collard Craig A converted options into 84,810 shares, increasing direct ownership by 14% to 757,885 units (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 47d
  SEC Form 4 filed by Forbes William P

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 47d
  SEC Form 4 filed by Collard Craig A

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 47d
  SEC Form 4 filed by Duarte Ira

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 62d
  SEC Form 4 filed by Collard Craig A

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 124d
  Director Cusack Thomas was granted 53,960 shares (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 124d
  SEC Form 4 filed by EVP, Chief Financial Officer Duarte Ira

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 124d
  Director Johnson Craig A was granted 53,960 shares (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 124d
  Director Kaseta Michael was granted 53,960 shares (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 124d
  Director Christian Waage was granted 53,960 shares (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 124d
  SEC Form 4 filed by Chief Executive Officer Collard Craig A

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 124d
  Director Dissanaike Sharmila was granted 53,960 shares (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 124d
  SEC Form 4 filed by EVP, Chief Development Officer Forbes William P

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 124d
  SEC Form 4 filed by Chief Operating Officer Hensley Mark Earl

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 124d
  Director Morgan Adam was granted 53,960 shares, increasing direct ownership by 77% to 123,737 units (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 124d
  EVP, Chief Financial Officer Duarte Ira converted options into 11,695 shares, increasing direct ownership by 6% to 195,356 units (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 124d
  Chief Executive Officer Collard Craig A converted options into 34,789 shares, increasing direct ownership by 6% to 571,710 units (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 124d
  EVP, Chief Development Officer Forbes William P converted options into 11,695 shares, increasing direct ownership by 7% to 181,773 units (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 138d
  EVP, Chief Development Officer Forbes William P converted options into 3,875 shares, increasing direct ownership by 2% to 170,078 units (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 138d
  EVP, Chief Financial Officer Duarte Ira converted options into 3,875 shares, increasing direct ownership by 2% to 183,661 units (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 138d
  Chief Executive Officer Collard Craig A converted options into 13,797 shares, increasing direct ownership by 3% to 536,921 units (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 207d
  Director Cusack Thomas was granted 37,879 shares (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 212d
  SEC Form 3 filed by new insider Cusack Thomas

  3 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 215d
  EVP, Chief Development Officer Forbes William P converted options into 11,694 shares, increasing direct ownership by 8% to 166,203 units (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 215d
  EVP, Chief Financial Officer Duarte Ira converted options into 11,694 shares, increasing direct ownership by 7% to 179,786 units (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 215d
  Chief Executive Officer Collard Craig A converted options into 34,789 shares, increasing direct ownership by 7% to 523,124 units (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 229d
  EVP, Chief Development Officer Forbes William P converted options into 3,874 shares, increasing direct ownership by 3% to 154,509 units (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 229d
  EVP, Chief Financial Officer Duarte Ira converted options into 3,874 shares, increasing direct ownership by 2% to 168,092 units (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 229d
  Chief Executive Officer Collard Craig A converted options into 13,797 shares, increasing direct ownership by 3% to 488,335 units (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 233d
  Large owner Rubric Capital Management Lp converted options into 946,100 shares (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 299d
  Large owner Rubric Capital Management Lp bought $3,580,838 worth of shares (2,387,225 units at $1.50) (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 299d
  Director Morgan Adam bought $2,649,819 worth of shares (1,766,546 units at $1.50) (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 307d
  EVP, Chief Development Officer Forbes William P converted options into 11,695 shares, increasing direct ownership by 8% to 150,635 units (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 307d
  EVP, Chief Financial Officer Duarte Ira converted options into 11,695 shares, increasing direct ownership by 8% to 164,218 units (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 307d
  Chief Executive Officer Collard Craig A converted options into 34,789 shares, increasing direct ownership by 8% to 474,538 units (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 320d
  EVP, Chief Development Officer Forbes William P converted options into 3,874 shares, increasing direct ownership by 3% to 138,940 units (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 320d
  EVP, Chief Financial Officer Duarte Ira converted options into 3,874 shares, increasing direct ownership by 3% to 152,523 units (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 320d
  Chief Executive Officer Collard Craig A converted options into 13,797 shares, increasing direct ownership by 3% to 439,749 units (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 355d
  EVP, Chief Financial Officer Duarte Ira converted options into 12,500 shares, increasing direct ownership by 9% to 148,649 units (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 363d
  EVP, Chief Development Officer Forbes William P converted options into 12,500 shares, increasing direct ownership by 10% to 135,066 units (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 396d
  SEC Form 4 filed by Chief Operating Officer Hensley Mark Earl

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 401d
  EVP, Chief Development Officer Forbes William P converted options into 11,694 shares, increasing direct ownership by 11% to 122,566 units (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 401d
  EVP, Chief Financial Officer Duarte Ira converted options into 11,694 shares, increasing direct ownership by 9% to 136,149 units (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 401d
  Chief Executive Officer Collard Craig A converted options into 34,789 shares, increasing direct ownership by 9% to 425,952 units (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 404d
  SEC Form 4 filed by Chief Operating Officer Hensley Mark Earl

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 404d
  SEC Form 3 filed by new insider Hensley Mark Earl

  3 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 411d
  EVP, Chief Development Officer Forbes William P converted options into 3,875 shares, increasing direct ownership by 4% to 110,872 units (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 411d
  EVP, Chief Financial Officer Duarte Ira converted options into 3,875 shares, increasing direct ownership by 3% to 124,455 units (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 411d
  Chief Executive Officer Collard Craig A converted options into 13,796 shares, increasing direct ownership by 4% to 391,163 units (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 430d
  Chief Executive Officer Collard Craig A converted options into 62,500 shares, increasing direct ownership by 20% to 377,367 units (SEC Form 4)

  4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 488d
  Amendment: Director Kaseta Michael was granted 17,950 shares, increasing direct ownership by 47% to 55,829 units (SEC Form 4)

  4/A - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 488d
  Amendment: Director Morgan Adam was granted 17,950 shares, increasing direct ownership by 35% to 69,777 units (SEC Form 4)

  4/A - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 488d
  Amendment: Director Dissanaike Sharmila was granted 17,950 shares, increasing direct ownership by 26% to 87,180 units (SEC Form 4)

  4/A - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 488d
  Amendment: Director Johnson Craig A was granted 17,950 shares, increasing direct ownership by 27% to 83,770 units (SEC Form 4)

  4/A - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 488d
  Amendment: Director Rodriguez Susan was granted 17,950 shares, increasing direct ownership by 26% to 87,180 units (SEC Form 4)

  4/A - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
• 488d
  Amendment: Director Christian Waage was granted 17,950 shares, increasing direct ownership by 27% to 84,130 units (SEC Form 4)

  4/A - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)